Join
Live feed
·
INSIDERFilingvia Quantisnow
Travere Therapeutics Inc. logo

SVP, CHIEF ACCOUNTING OFFICER Calvin Sandra sold $104,760 worth of shares (2,910 units at $36.00), decreasing direct ownership by 6% to 45,635 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TVTX· Travere Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.